Cardiol Therapeutics Inc.
CRDL.TO
TSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 19.18M | 18.00M | 14.17M | 12.60M | 11.53M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 29.40M | 28.16M | 23.50M | 22.54M | 22.07M |
| Operating Income | -29.40M | -28.16M | -23.50M | -22.54M | -22.07M |
| Income Before Tax | -26.80M | -26.57M | -21.66M | -22.41M | -20.84M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -26.80 | -26.57 | -21.66 | -22.41 | -20.84 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -26.80M | -26.57M | -21.66M | -22.41M | -20.84M |
| EBIT | -29.40M | -28.16M | -23.50M | -22.54M | -22.07M |
| EBITDA | -29.28M | -28.06M | -23.38M | -22.41M | -21.92M |
| EPS Basic | -0.38 | -0.39 | -0.33 | -0.34 | -0.32 |
| Normalized Basic EPS | -0.24 | -0.24 | -0.20 | -0.21 | -0.20 |
| EPS Diluted | -0.38 | -0.39 | -0.33 | -0.34 | -0.32 |
| Normalized Diluted EPS | -0.24 | -0.24 | -0.20 | -0.21 | -0.20 |
| Average Basic Shares Outstanding | 286.26M | 271.01M | 265.66M | 261.02M | 257.85M |
| Average Diluted Shares Outstanding | 286.26M | 271.01M | 265.66M | 261.02M | 257.85M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |